Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

November is Alzheimer's Awareness Month, and if you have a loved one in the beginning stages of the disease, a local clinical ...

Thousands of community members attended the 2024 Walk to End Alzheimer's in Richmond on Saturday, and 8News spoke to several ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...

Two blood tests currently in development have shown 'very high accuracy' in detecting tell-tale signs of Alzheimer's disease, ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among ...

Cassava Sciences' RETHINK-ALZ trial is nearing data release. See why SAVA stock could see volatility depending on trial ...

The Phase 1a clinical trial was a randomized, double-blind ... that points to the role of soluble amyloid-beta oligomers (A O) as a primary driver of Alzheimer's disease pathology. By selectively ...

Roche recently presented data at the 17th Clinical Trials in Alzheimer’s Disease congress (CTAD) on two new Alzheimer’s disease blood tests currently in development. Both tests reportedly show ...